PT - JOURNAL ARTICLE AU - McKenzie, Lauren AU - Shoukat, Affan AU - Wong, Kai On AU - Itahashi, Koju AU - Yasuda, Eiji AU - Demarsh, Alex AU - Khan, Kamran TI - Inferring the true number of SARS-CoV-2 infections in Japan AID - 10.1101/2022.04.01.22273214 DP - 2022 Jan 01 TA - medRxiv PG - 2022.04.01.22273214 4099 - http://medrxiv.org/content/early/2022/04/03/2022.04.01.22273214.short 4100 - http://medrxiv.org/content/early/2022/04/03/2022.04.01.22273214.full AB - Introduction In Japan, as of December 31, 2021, more than 1.73 million laboratory-confirmed cases have been reported. However, the actual number of infections is likely to be under-ascertained due to the epidemiological characteristics such as mild and subclinical infections and limited testing availability in the early days of the pandemic. In this study, we infer the true number of infections in Japan between January 16, 2020, and December 31, 2021, using a statistical modelling framework that combines data on reported cases and fatalities.Methods We used reported daily COVID-19 deaths stratified into 8 distinct age-groups and age-specific infection fatality ratios (IFR) to impute the true number of infections. Estimates of IFR were informed from published studies as well seroprevalence studies conducted in Japan. To account for the uncertainty in IFR estimates, we sampled values from relevant distributions.Results We estimated that as of December 31, 2021, 2.90 million (CrI: 1.77 to 4.27 million) people had been infected in Japan, which is 1.68 times higher than the 1.73 million reported cases. Our meta-analysis confirmed that these findings were consistent with the intermittent seroprevalence studies conducted in Japan.Conclusions We have estimated that a substantial number of COVID-19 infections in the country were unreported, particularly in adults. Our approach provides a more realistic assessment of the true underlying burden of COVID-19. The results of this study can be used as fundamental components to strengthen population health control and surveillance measures.Competing Interest StatementKamran Khan is the founder of BlueDot, a social enterprise that develops digital technologies for public health. Lauren McKenzie, Affan Shoukat, Alex Demarsh, Kai On Wong, and Kamran Khan are employed at BlueDot. Koju Itahashi and Eiji Yasuda are employed by Meiji Seika Pharma Co.Funding StatementThis study did not receive any fundingAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors and available online at https://github.com/BlueDot-global/true_infections https://github.com/BlueDot-global/true_infections